A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition to Oral Antidiabetes Drugs (OADs)

Inclusion criteria :

  • Patients with Type 2 diabetes (T2D) using any types of basal insulin alone or in combination with up to 2 OADs (oral antidiabetic drugs)
  • Patient has given written informed consent to participate in the study in accordance with local regulations